CD274 and esophageal cancer: For advanced esophageal cancer post-first-line chemotherapy, the KEYNOTE-181 trial demonstrated that pembrolizumab significantly prolonged median OS versus chemotherapy in patients with PD-L1 CPS ≥10, with fewer AEs (62), leading to its approval by the NMPA in June 2020.